Cargando…
Combination therapies for cancer: challenges and opportunities
BACKGROUND: Gastrointestinal cancers represent a major challenge to public health. Pancreatic cancer is the most lethal cancer among all gastrointestinal cancers. Most patients cannot meet the criteria of resection at diagnosis, indicating these patients will have dismal prognosis. MAIN TEXT: Neoadj...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161484/ https://www.ncbi.nlm.nih.gov/pubmed/37143031 http://dx.doi.org/10.1186/s12916-023-02852-4 |
_version_ | 1785037504605323264 |
---|---|
author | Zhou, Zhijun Edil, Barish H. Li, Min |
author_facet | Zhou, Zhijun Edil, Barish H. Li, Min |
author_sort | Zhou, Zhijun |
collection | PubMed |
description | BACKGROUND: Gastrointestinal cancers represent a major challenge to public health. Pancreatic cancer is the most lethal cancer among all gastrointestinal cancers. Most patients cannot meet the criteria of resection at diagnosis, indicating these patients will have dismal prognosis. MAIN TEXT: Neoadjuvant chemotherapy helps some patients regain the opportunity of radical resection. An optimal regimen of chemotherapy is one that maximizes the anti-tumor efficacy while maintaining a relatively manageable safety profile. The development of surgical procedures further improves the outcomes of these patients. CONCLUSIONS: Combination therapies in a multidisciplinary manner that involves modified chemotherapy regimen, radical resection, and intestine auto-transplantation may provide the currently best possible care to patients with locally advanced pancreatic cancer. |
format | Online Article Text |
id | pubmed-10161484 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101614842023-05-06 Combination therapies for cancer: challenges and opportunities Zhou, Zhijun Edil, Barish H. Li, Min BMC Med Opinion BACKGROUND: Gastrointestinal cancers represent a major challenge to public health. Pancreatic cancer is the most lethal cancer among all gastrointestinal cancers. Most patients cannot meet the criteria of resection at diagnosis, indicating these patients will have dismal prognosis. MAIN TEXT: Neoadjuvant chemotherapy helps some patients regain the opportunity of radical resection. An optimal regimen of chemotherapy is one that maximizes the anti-tumor efficacy while maintaining a relatively manageable safety profile. The development of surgical procedures further improves the outcomes of these patients. CONCLUSIONS: Combination therapies in a multidisciplinary manner that involves modified chemotherapy regimen, radical resection, and intestine auto-transplantation may provide the currently best possible care to patients with locally advanced pancreatic cancer. BioMed Central 2023-05-04 /pmc/articles/PMC10161484/ /pubmed/37143031 http://dx.doi.org/10.1186/s12916-023-02852-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Opinion Zhou, Zhijun Edil, Barish H. Li, Min Combination therapies for cancer: challenges and opportunities |
title | Combination therapies for cancer: challenges and opportunities |
title_full | Combination therapies for cancer: challenges and opportunities |
title_fullStr | Combination therapies for cancer: challenges and opportunities |
title_full_unstemmed | Combination therapies for cancer: challenges and opportunities |
title_short | Combination therapies for cancer: challenges and opportunities |
title_sort | combination therapies for cancer: challenges and opportunities |
topic | Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161484/ https://www.ncbi.nlm.nih.gov/pubmed/37143031 http://dx.doi.org/10.1186/s12916-023-02852-4 |
work_keys_str_mv | AT zhouzhijun combinationtherapiesforcancerchallengesandopportunities AT edilbarishh combinationtherapiesforcancerchallengesandopportunities AT limin combinationtherapiesforcancerchallengesandopportunities |